A TWO-ARM, SINGLE CENTER PHASE 1B TRIAL OF BAVITUXIMAB PLUS IPILIMUMAB IN ADVANCED MELANOMA PATIENTS
Phase of Trial: Phase I
Latest Information Update: 03 Jan 2017
Price : $35 *
At a glance
- Drugs Bavituximab (Primary) ; Ipilimumab
- Indications Malignant melanoma
- Focus Adverse reactions; Proof of concept
- 28 Dec 2016 Status changed from active, no longer recruiting to discontinued.
- 10 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 23 Apr 2014 Status changed from not yet recruiting to recruiting, as reported by a Peregrine Pharmaceuticals media release.